Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Fractyl Health, Inc. ( (GUTS) ) has provided an update.
On May 11, 2026, Fractyl Health, Inc. announced it had received authorization in the Netherlands to begin a Phase 1/2 first-in-human trial of RJVA-001, the first clinical candidate from its Rejuva Smart GLP-1 gene therapy platform for type 2 diabetes. With RJVA-001 believed to be the first AAV-based gene therapy to enter clinical development for type 2 diabetes, the approval elevates Fractyl to a dual clinical-stage company, alongside its Revita program in pivotal development for post-GLP-1 weight maintenance, with Rejuva’s early clinical work funded within its existing cash runway into early 2027.
RJVA-001 is a one-time, beta-cell–targeted gene therapy delivered via endoscopic ultrasound-guided intrapancreatic infusion, designed to enable nutrient-responsive, physiologic GLP-1 expression in the pancreas and potentially avoid side effects associated with chronic systemic GLP-1 exposure. The open-label, multicenter Phase 1/2 trial will enroll adults with inadequately controlled type 2 diabetes despite GLP-1 receptor agonists and multiple oral agents, assessing safety, tolerability and preliminary efficacy over 12 months, with an optional expansion cohort and long-term follow-up of up to five years, and Fractyl also plans trial sites in Australia pending regulatory feedback.
The most recent analyst rating on (GUTS) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Fractyl Health, Inc. stock, see the GUTS Stock Forecast page.
Spark’s Take on GUTS Stock
According to Spark, TipRanks’ AI Analyst, GUTS is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, accelerating cash burn, and elevated leverage) and limited earnings-based valuation support (negative P/E). Offsetting factors include constructive technical momentum and a generally positive earnings-call outlook with clear, near-dated clinical/regulatory catalysts, though corporate-event risk is elevated due to the Nasdaq minimum bid notice.
To see Spark’s full report on GUTS stock, click here.
More about Fractyl Health, Inc.
Fractyl Health, Inc. is a clinical-stage metabolic therapeutics company focused on novel treatments for obesity and type 2 diabetes. Its pipeline includes Revita, a procedural therapy in pivotal development for post-GLP-1 weight maintenance, and Rejuva, an adeno-associated virus-based gene therapy platform targeting the pancreas to address the root causes of metabolic disease.
Headquartered in Burlington, Massachusetts, Fractyl aims to shift metabolic care from chronic symptom management toward prevention and potential reversal of disease. The Rejuva platform is developing locally delivered gene therapies such as RJVA-001 for type 2 diabetes and RJVA-002 for obesity, using advanced delivery systems and proprietary screening methods to create disease-modifying interventions.
Average Trading Volume: 2,137,435
Technical Sentiment Signal: Sell
Current Market Cap: $119.7M
For detailed information about GUTS stock, go to TipRanks’ Stock Analysis page.